Avingtrans (AVG) AI Stock Analysis

• Market Cap: £179.65M
• Dividend Yield: 1.02%
• Average Volume (3M): 61.23K
• Price to Earnings (P/E): 10.7
• Beta (1Y): 0.55
• Revenue Growth: 14.49%
• EPS Growth: 76.33%
• Country: UK
• Employees: 941
• Sector: Industrials
• Sector Strength: 72
• Industry: Industrial - Machinery
• EPS (TTM): 0.15
• Shares Outstanding: 33,269,320
• 10 Day Avg. Volume: 57,336
• 30 Day Avg. Volume: 61,226
• PEG Ratio: 0.25
• Price to Book (P/B): 1.20
• Price to Sales (P/S): 0.87
• P/FCF Ratio: 15.42
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.3
• Revenue Forecast (FY): £175.02M

• Rating: 70 Outperform
• Price Target: 594.00 p ▲(23.75% Upside)
• Action: Upgraded Date: 12/07/25
• Date: Action: Upgraded 12/07/25

Avingtrans' overall stock score is driven by strong financial performance and positive corporate events, which enhance its growth prospects. While the technical analysis suggests a neutral trend, the valuation indicates potential overvaluation. The absence of earnings call data limits insights into management's outlook.

Positive Factors

Aftermarket / Through-life Support

Avingtrans earns recurring revenue from aftermarket, spares and through-life support for installed equipment. This creates more predictable, higher-margin follow-on income versus one-off builds, supports customer stickiness and smooths revenue volatility across project cycles.

Low Leverage / Strong Balance Sheet

A low debt-to-equity ratio gives Avingtrans durable financial flexibility to fund project working capital, absorb delays, invest in capacity or pursue small M&A without stressing liquidity. A conservative capital structure reduces refinancing risk through industry cycles.

Improved Free Cash Flow

Material improvement in free cash flow and a high FCF-to-net-income ratio point to stronger cash conversion. This supports reinvestment, capital expenditure for precision manufacturing, funding of working capital on projects and reduces dependence on external financing.

Negative Factors

Modest Net Margin

Avingtrans' net margin around 4% is low for engineering project work, leaving limited buffer against cost inflation, project overruns or pricing pressure. Small margin headroom increases sensitivity of earnings to execution risks and could constrain returns on incremental investment.

Slow Revenue Growth

Modest top-line growth under 5% indicates limited organic expansion and reliance on winning specific contracts or aftermarket upsell. Slow revenue momentum can limit economies of scale, reduce leverage on fixed costs and make margin expansion more difficult over the medium term.

Cyclical & Contract Concentration

Heavy exposure to nuclear and aerospace and project-based contracts creates cyclical demand and lumpy revenue. Concentrated end-markets and bespoke project risk increase sensitivity to sector budgets, regulatory cycles and contract execution, amplifying cash and margin volatility.

Avingtrans Business Overview & Revenue Model

Company Description

Avingtrans plc manufactures and sells engineered components, systems, and services to the energy, medical, and infrastructure industries worldwide. It operates in three segments: Energy-EPM, Energy-PSRE, and Medical-MII. The company designs, manufactures, integrates, and services electric motors and pumps, steam turbines, gas compressors, pressure vessels, blast doors, containers, and skidded systems. It also designs and manufactures equipment for the medical, science and research communities, including products for medical diagnostic equipment; high performance pressure, vacuum vessels, and composite materials for research organizations; and superconducting magnets and helium-free cryogenic systems for use in magnetic resonance imaging and nuclear magnetic resonance. The company was incorporated in 1985 and is based in Chatteris, the United Kingdom.

How the Company Makes Money

Avingtrans makes money primarily by selling engineered products and engineering services to industrial customers, with revenues typically generated through a combination of project-based contracts and repeat aftermarket/support work. Key revenue streams include: 1) Engineered equipment and systems (project and contract revenue): The group designs and manufactures specialist equipment and components—particularly for nuclear applications—sold under customer contracts. Revenue is earned as equipment is delivered and/or as project milestones are achieved, depending on contract structure. 2) Engineering services and project execution: In addition to physical products, Avingtrans provides engineering design, integration, installation, commissioning and project management services. This generates service revenue that is often tied to hours worked, deliverables completed, or contracted project milestones. 3) Aftermarket, spares and through-life support: For installed equipment, the company can earn ongoing revenue from maintenance, refurbishment, spares supply, inspection and other support services over the asset’s life. This can provide more recurring and repeat business than one-off build projects. 4) Advanced Engineering (aerospace/precision manufacturing): The Advanced Engineering activity earns revenue from manufacturing high-precision components/assemblies for aerospace and other customers. Revenue is generated from production orders (often repeat orders) and may include additional income from associated machining, testing and quality/compliance activities where contracted. Material factors influencing earnings: - Customer end-markets: A significant driver is demand in nuclear (including decommissioning and waste management programs) and aerospace/industrial production cycles. - Contract mix: Profitability and cash generation depend on the balance between higher-value engineered projects and steadier aftermarket/support work, as well as the terms and execution of individual contracts. - Partnerships: null

Avingtrans Financial Statement Overview

Summary

Avingtrans exhibits robust financial performance with consistent revenue growth and improving profitability margins. The balance sheet is strong, characterized by low leverage and effective equity utilization. Cash flow metrics show significant improvement, enhancing the company's financial flexibility. Overall, Avingtrans is well-positioned for future growth, though maintaining margin improvements and cash flow stability will be crucial.

Income Statement

Avingtrans has shown consistent revenue growth over the years, with a notable increase of 3.96% in the latest period. The gross profit margin is healthy at 30.28%, although it has slightly decreased from previous years. The net profit margin has improved to 4.19%, indicating better profitability. EBIT and EBITDA margins have also shown positive trends, reflecting efficient operations.

Balance Sheet

The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.23, suggesting prudent financial management. Return on equity has improved to 5.80%, indicating effective use of equity to generate profits. The equity ratio remains stable, showing a solid capital structure.

Cash Flow

Avingtrans has demonstrated significant improvement in free cash flow, with a growth rate of 61.75%. The operating cash flow to net income ratio is 0.21, indicating moderate cash generation relative to net income. The free cash flow to net income ratio of 0.76 reflects a strong cash conversion cycle.

Breakdown	TTM	May 2024	May 2023	May 2022	May 2021	May 2020
Income Statement
Total Revenue	155.49M	156.41M	136.62M	116.44M	99.08M	98.52M
Gross Profit	48.50M	47.36M	44.04M	36.86M	32.59M	28.38M
EBITDA	16.70M	15.75M	12.54M	13.20M	12.02M	11.03M
Net Income	7.06M	6.56M	3.66M	5.19M	6.48M	3.99M
Balance Sheet
Total Assets	196.40M	192.76M	186.34M	155.41M	154.69M	142.61M
Cash, Cash Equivalents and Short-Term Investments	5.62M	8.56M	12.12M	17.72M	24.29M	30.08M
Total Debt	27.28M	25.47M	23.96M	8.58M	10.96M	9.80M
Total Liabilities	76.54M	77.53M	73.33M	46.96M	48.88M	43.65M
Stockholders Equity	117.28M	113.14M	110.44M	106.04M	103.82M	97.30M
Cash Flow
Free Cash Flow	11.11M	8.80M	-11.06M	985.00K	-1.10M	4.03M
Operating Cash Flow	14.29M	11.61M	1.33M	9.68M	3.88M	6.45M
Investing Cash Flow	-14.67M	-14.29M	-13.58M	-12.52M	-9.35M	24.56M
Financing Cash Flow	-4.05M	-436.00K	6.78M	-3.40M	-371.00K	-5.85M

Avingtrans Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 480.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AVG, the sentiment is Negative. The current price of 480 is below the 20-day moving average (MA) of 567.75, below the 50-day MA of 559.40, and below the 200-day MA of 481.98, indicating a neutral trend. The MACD of -3.46 indicates Positive momentum. The RSI at 38.25 is Neutral, neither overbought nor oversold. The STOCH value of 40.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:AVG.

Avingtrans Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVG	70 Outperform	£179.65M	10.69	5.87%	1.02%	14.49%	76.33%
CGS	65 Neutral	£112.82M	7.63	3.82%	6.69%	-13.30%	-60.03%
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
BOY	62 Neutral	£1.21B	22.48	4.34%	3.30%	-6.95%	-52.08%
MGAM	62 Neutral	£575.90M	28.89	8.04%	4.87%	-7.30%	-59.71%
MPAC	61 Neutral	£90.67M	-2.99	-17.46%	―	21.17%	-237.25%
ITM	44 Neutral	£394.50M	-8.61	-18.47%	―	57.73%	-67.12%

Avingtrans Corporate Events

Avingtrans Lifts Profit and Dividend as Nuclear and Imaging Units Gain Momentum

Avingtrans reported flat first-half revenue of £78.1m but improved profitability, with gross margin rising to 31.7%, adjusted EBITDA up 10.4% to £9.6m and adjusted profit before tax up 27.1% to £5.7m. Cash generation strengthened, net debt was held at £12.3m despite continued investment in medical imaging and new nuclear technologies, and the interim dividend was lifted to 2.0p per share.

The Advanced Engineering Systems division delivered another strong performance, benefiting from surging global energy demand linked to AI and data centre growth, including a $16m new nuclear contract in South Korea and new UK infrastructure work. The Medical and Industrial Imaging division reduced losses as revenue grew 33%, helped by US FDA 510(k) clearance for Adaptix’s orthopaedic 3D X‑ray system, and with leadership changes and a robust order book, the board signalled confidence in meeting full-year expectations and executing its buy-build-exit strategy to enhance shareholder value.

The most recent analyst rating on (GB:AVG) stock is a Buy with a £650.00 price target. To see the full list of analyst forecasts on Avingtrans stock, see the GB:AVG Stock Forecast page.

Avingtrans Issues New Shares Following Employee Option Exercises

Avingtrans has announced that certain non-board employees have exercised 138,900 options under the company’s CSOP scheme, resulting in the issue of an equivalent number of new ordinary shares and an application for their admission to trading on AIM, expected to take effect on 4 February 2026. Following this issuance, Avingtrans will have 33,269,322 ordinary shares in issue with no shares held in treasury, a change that slightly increases the company’s share capital and affects the total voting rights figure that shareholders must use when assessing regulatory disclosure thresholds under the FCA’s transparency rules.

The most recent analyst rating on (GB:AVG) stock is a Buy with a £638.00 price target. To see the full list of analyst forecasts on Avingtrans stock, see the GB:AVG Stock Forecast page.

Avingtrans Confirms In-Line First-Half Trading and Eyes Growth from AI, Data Centre and Nuclear Tailwinds

Avingtrans reported that trading for the first six months to 30 November 2025 was in line with management expectations, underpinned by continuing positive momentum across the Group, particularly in businesses exposed to AI and data centre demand and to the revival of nuclear power markets. The company highlighted confidence in meeting market expectations for FY26, citing a buoyant opportunity pipeline and active contract discussions expected to translate into growth from FY27 onwards, while also strengthening its Medical and Industrial Imaging division with the earlier-than-planned appointment of Stuart Gall as CEO and confirming that interim results will be published on 25 February 2026.

The most recent analyst rating on (GB:AVG) stock is a Buy with a £597.00 price target. To see the full list of analyst forecasts on Avingtrans stock, see the GB:AVG Stock Forecast page.

Avingtrans Grants Share Options Tied to Inflation-Linked EPS Growth

Avingtrans plc has granted options over 293,000 ordinary shares to non-PDMR employees under its Share Option Plan, with an exercise price of 515.0 pence per share, as part of its long-term incentive arrangements. The options will vest after three years and are contingent on the company’s adjusted earnings per share at least matching the increase in the Retail Prices Index over the vesting period, aligning employee rewards with both company performance and inflation-protected shareholder value.

The most recent analyst rating on (GB:AVG) stock is a Buy with a £539.00 price target. To see the full list of analyst forecasts on Avingtrans stock, see the GB:AVG Stock Forecast page.

Avingtrans Names Stuart Gall to Lead Medical and Industrial Imaging Division

Avingtrans has appointed experienced MedTech executive Stuart Gall as Chief Executive Officer of its medical and industrial imaging division, effective 1 January 2026, tasking him with driving the strategic development and commercialisation of portfolio businesses Adaptix, Magnetica and Scientific Magnets. Gall’s track record in scaling medical technology companies from university spin-outs to globally partnered, publicly listed businesses is expected to accelerate market adoption of Avingtrans’ disruptive imaging technologies and support the Group’s efforts to enhance the value of this division for shareholders and strengthen its positioning in high-growth medical and industrial imaging markets.

The most recent analyst rating on (GB:AVG) stock is a Buy with a £539.00 price target. To see the full list of analyst forecasts on Avingtrans stock, see the GB:AVG Stock Forecast page.